Tiziana Life Sciences announced that it will advance its intranasal foralumab anti-CD3 monoclonal antibody into clinical development for the treatment of hemorrhagic stroke after a pre-clinical study in a model of intracerebral hemorrhage demonstrated improvement at one month post-dose. The company did not provide details of the study.
The company recently announced plans for a Phase 2 trial of intranasal foralumab in patients with non-active secondary progressive multiple sclerosis. Intranasal foralumab has also been studied for the treatment of COVID-19, and the company cites a recent publication discussing how the nasal spray can affect T cell inflammatory response following COVID-19.
Tiziana Executive Chairman and CEO Gabriele Cerrone said, “Less than 10% of people who have hemorrhagic stroke completely recover, and most are left with a disability that could include lasting effects on their speech and physical function. Intranasal anti-CD3 monoclonal antibody showed improved motor and cognitive outcomes at one-month post-intracerebral hemorrhage which is very exciting. We are actively exploring the clinical development pathway in intracerebral hemorrhage using intranasal foralumab, the first-ever fully human anti-CD3 monoclonal antibody in patients suffering from a hemorrhagic stroke. This new exciting finding further validates our decision to focus on the clinical development of our lead asset, intranasal foralumab. This potential immunomodulatory therapy represents a novel avenue for treatment of inflammatory diseases.”
Read the Tiziana Life Sciences press release.
